2025 ICD-10-CM Diagnosis Code C86.5

Angioimmunoblastic T-cell lymphoma

C86.5 should not be used for reimbursement purposes as there are multiple codes below it that contain a greater level of detail.
ICD-10-CM C86.5 is a new 2025 ICD-10-CM code that became effective on October 1, 2024.
This is the American ICD-10-CM version of C86.5 – other international versions of ICD-10 C86.5 may differ.

Applicable To

The following code(s) above C86.5 contain annotation back-references

that may be applicable to C86.5:

Approximate Synonyms

Clinical Information

A disorder characterized by proliferation of arborizing small vessels, prominent immunoblastic proliferations and amorphous acidophilic interstitial material. Clinical manifestations include fever, sweats, weight loss, generalized lymphadenopathy and frequently hepatosplenomegaly.
A mature t-cell non-hodgkin lymphoma, characterized by systemic disease and a polymorphous infiltrate involving lymph nodes. It occurs in the middle aged and elderly, with an equal incidence in males and females. The clinical course is typically aggressive. (who, 2001)
An aggressive (fast-growing) type of t-cell non-hodgkin lymphoma marked by enlarged lymph nodes and hypergammaglobulinemia (increased antibodies in the blood). Other symptoms may include a skin rash, fever, weight loss, or night sweats.

Code History

2016 (effective 10/1/2015): New code (first year of non-draft ICD-10-CM)
2017 (effective 10/1/2016): No change
2018 (effective 10/1/2017): No change
2019 (effective 10/1/2018): No change
2020 (effective 10/1/2019): No change
2021 (effective 10/1/2020): No change
2022 (effective 10/1/2021): No change
2023 (effective 10/1/2022): No change
2024 (effective 10/1/2023): No change
2025 (effective 10/1/2024): Deleted code
2025 (effective 10/1/2024): New code

Diagnosis Index entries containing back-references to C86.5:

Lymphadenopathy (generalized) R59.1
- angioimmunoblastic, with dysproteinemia C86.5- (AILD)
Lymphoma (of) (malignant) C85.90
- angioimmunoblastic T-cell C86.5-